값Q4, 24Q4, 25TTM판매비·일반관리비———연구개발———영업 이익———비영업 수익, 합계———이자비용(자본화한 이자 차감 후)———이자비용을 제외한 비영업 수익———비정상 수입/지출———세전소득———지분법 손익———세금———비지배 지분———세후 기타 수익/비용———중단된 사업 부문 제외 순이익———중단된 사업———순이익———희석보정———우선배당———보통주주에게 귀속되는 희석 순이익———주당 순이익(기본 EPS)———희석 주당 순이익 (희석 EPS)———평균 발행주식수———희석주식수———EBITDA———EBIT———매출원가———기타 매출원가———감가상각 및 무형자산 상각 (현금흐름)———
Alcon Inc. Ordinary Shares
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.